Evidence map›Paper›PMID 40078724›Full record

ArticleBiosafety and health2024

A novel method for identifying SARS-CoV-2 infection mutants via an epitope-specific CD8

Congling Qiu, Bo Peng, Chanchan Xiao, Pengfei Chen, Lipeng Mao, Xiaolu Shi, Zhen Zhang, Ziquan Lv, Qiuying Lv, Xiaomin Zhang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosafety and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Congling QiuDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Kangtai Biological Vaccine Industry Research Institute/Disease Prevention and Control Institute of Jinan University, Guangzhou 510632, China.
Bo PengShenzhen Center for Disease Control and Prevention, Shenzhen 518020, China.
Chanchan XiaoDepartment of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou 510632, China.
Pengfei ChenDepartment of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou 510632, China.
Lipeng MaoDepartment of Systems Biomedical Sciences, School of Medicine, Jinan University, Guangzhou 510632, China.
Xiaolu ShiMicrobiology Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen 518020, China.
Zhen ZhangDepartment of Communicable Diseases Control and Prevention, Shenzhen Center for Disease Control and Prevention, Shenzhen 518020, China.
Ziquan LvCentral Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen 518020, China.
Qiuying LvDepartment of Communicable Diseases Control and Prevention, Shenzhen Center for Disease Control and Prevention, Shenzhen 518020, China.
Xiaomin ZhangMicrobiology Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen 518020, China.
Jiaxin LiDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Kangtai Biological Vaccine Industry Research Institute/Disease Prevention and Control Institute of Jinan University, Guangzhou 510632, China.
Yanhao HuangDepartment of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou 510632, China.
Qinghua HuShenzhen Center for Disease Control and Prevention, Shenzhen 518020, China.
Guobing ChenDepartment of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou 510632, China.
Xuan ZouShenzhen Center for Disease Control and Prevention, Shenzhen 518020, China.
Xiaofeng LiangDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Kangtai Biological Vaccine Industry Research Institute/Disease Prevention and Control Institute of Jinan University, Guangzhou 510632, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the outbreak of the coronavirus disease 2019 (COVID-19) epidemic in 2019, the public health system has faced enormous challenges. Tracking the individuals who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key step for interrupting chains of transmission of SARS-CoV-2 and reducing COVID-19-associated mortality. With the increasing of asymptomatic infections, it is difficult to track asymptomatic infections through epidemiological surveys and virus whole-genome sequencing. However, due to the cross-reactivity of neutralizing antibodies produced by multiple virus subtypes, neutralizing antibody detection cannot be used to determine whether an individual has a history of infection with a specific subtype of SARS-CoV-2. We recruited 4 human leukocyte antigen A2 (HLA-A2) infections, 15 individuals who received three doses of inactivated vaccines, and 30 breakthrough infections after vaccination and discussed a case-tracking approach to detect epitope-specific CD8

Indexed as

Asymptomatic coronavirus disease 2019 (COVID-19)ELISpotEpitopesSpecific CD8+ T cell

Identifiers

PMID40078724
PMCPMC11894948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.